drugset
drugset / Trial / NCT02161354

Safety and Efficacy Study of NTC-510 to Treat Pain Following Dental Surgery of Third Molars

NCT02161354 ↗

Phase 2 Terminated 52 enrolled NanoSHIFT LLC
RandomizedSingle-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy of a single dose NTC-510 or NTC-510A for dental pain following third molar extraction.

Timeline

Start
2014-06
Primary completion
2016-02
Completion
2016-02

Outcome

Outcome not reported

Stopped: “safety and efficacy after cohort 5 did not warrant further dose escalation”

Drugs

EvaluationDrugModalityDoseRoute
Subject NTC-510 Unknown 2 mg Oral
Subject NTC-510 Unknown 4 mg Oral
Subject NTC-510 Unknown 6 mg Oral
Subject NTC-510A Unknown 2 mg Oral
Subject NTC-510A Unknown 4 mg Oral
Subject NTC-510A Unknown 6 mg Oral

Indications

dental pulp disorder